Summary
Highlights
MOTS-c is a mitochondrial peptide increasing endurance performance, dropping body weight in obese mice, and mimicking fasting and exercise. It's considered a powerful mitochondrial peptide with potential benefits for health and longevity.
MOTS-c is a mitochondrial derived peptide that signals cells under metabolic stress to adapt. It enhances mitochondrial health, improves glucose and fat metabolism, increases antioxidant capacity, and boosts metabolic flexibility by activating AMPK, sirtuins, and PGC-1 alpha pathways. This leads to improved mitochondrial function, new mitochondrial creation, increased glucose uptake, fat utilization, and reduced inflammation.
CB4211 is a synthetic analog of MOTS-c with improved stability and bioavailability, made by Cobar. While their exact differences are proprietary, they are expected to have similar effects. MOTS-c is currently on the FDA's category 2 list, meaning it cannot be legally compounded, making CB4211 a potential future FDA-approved option.
A small Phase 1 human trial of CB4211 showed a 25% reduction in liver enzymes and 6% reduction in fasting blood sugar for non-alcoholic fatty liver disease. In obese mice, MOTS-c reduced blood sugar by 25% and body weight by 20%. Other potential uses, based on animal data, include anti-aging, longevity, and enhanced exercise performance.
MOTS-c improves mitochondrial function, impacting root causes of aging like energy regulation, chronic inflammation, and protein folding. Plasma levels of MOTS-c decrease with age, suggesting that supplementation could help stall the aging process. Mouse studies show improved healthspan, metabolic function, body composition, and functional strength, with trends towards increased lifespan by 7%.
Exogenous MOTS-c enhances exercise performance in mice, increasing running time by 12-15% and capacity by 30-50%. It primarily benefits slow-twitch muscle fibers, improving endurance but not necessarily maximal strength. MOTS-c also shows promise in inhibiting muscle loss (sarcopenia) due to aging, weight loss, or immobilization.
MOTS-c may help prevent osteoporosis and improve bone health by activating AMPK and promoting bone building. It also shows promise for neurodegenerative diseases like Alzheimer's and Parkinson's by addressing oxidative stress and mitochondrial dysfunction. Lower endogenous MOTS-c levels found in patients with these conditions or coronary artery disease suggest potential therapeutic benefits, though human data is very limited.
Limited human data means long-term safety is unknown. One concern is MOTS-c's potential to decrease folate levels and elevate homocysteine, linked to cardiovascular diseases. Strategies to mitigate this include monitoring folate and homocysteine levels, and taking methylated B vitamins on non-injection days. Another theoretical risk is overstressing mitochondria if continually activated, potentially limiting recovery and protein synthesis, or increasing oxidative stress.
To mitigate risk, regular lab work, symptom monitoring, and proper nutrient supplementation (magnesium glycinate, CoQ10, alpha-lipoic acid, L-carnitine) are suggested. MOTS-c is a potential top-tier peptide for anti-aging, longevity, and endurance exercise enhancement, especially for individuals with mild insulin resistance, obesity, or metabolic syndrome. It is prohibited by the World Anti-Doping Agency for athletes.
Subcutaneous injection is the preferred method as oral standard MOTS-c has low bioavailability. Dosing is speculative due to limited human data; a human equivalent dose of 3.33 mg/day (23 mg/week) for a 70kg adult is derived from effective animal studies. Less frequent dosing (e.g., three times per week) is suggested to mitigate risks and allow for adaptation, with 5-7.5 mg per injection. Timing injections 30 minutes before aerobic exercise and in the morning may optimize effects. A 4-week on, 4-week off cycle is suggested for anti-aging or exercise adaptations, based on hormesis principles. Sourcing from unregulated online suppliers is not recommended.